Evidence map›Paper›PMID 39241017›Full record

ArticlePLoS pathogens2024

The DNA loop release factor WAPL suppresses Epstein-Barr virus latent membrane protein expression to maintain the highly restricted latency I program.

Laura A Murray-Nerger, Davide Maestri, Xiang Liu, Zhixuan Li, Nina R Auld, Italo Tempera, Mingxiang Teng, Benjamin E Gewurz

Abstract read
In one paragraph

Article in PLoS pathogens, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Chromatin Control of EBV Infection and Latency.Current topics in microbiology and immunology · 2025
    Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Laura A Murray-NergerDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
Davide MaestriThe Wistar Institute, Philadelphia, Pennsylvania, United States of America.
Xiang LiuDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America.
Zhixuan LiDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
Nina R AuldDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
Italo TemperaThe Wistar Institute, Philadelphia, Pennsylvania, United States of America.
Mingxiang TengDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America.
Benjamin E GewurzDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.ORCID 0000-0002-3965-3418

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Aaron Robert Goldman · 1985 to 2026
$75.9M
INFECTIOUS DISEASE AND BASIC MICROBIOLOGICAL MECHANISMST32AI007061 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Marcia B Goldberg · 1985 to 2026
$12.1M
Targeting the Epigenetic and Metabolic Control of EBV-Epithelial CancersP01CA269043 · NCI · WISTAR INSTITUTE · PI Samantha Standish Soldan · 2023 to 2026
$12.0M
MOLECULAR BASIS OF VIRAL INFECTIVITYT32AI007245 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Aaron Gregory Schmidt · 1985 to 2026
$11.3M
B cell determinants of EBV latency (supplement)U01CA275301 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Ethel Cesarman, Benjamin Elison Gewurz · 2022 to 2026
$4.0M
Regulation of Viral Chromatin Architecture During EBV LatencyR01AI130209 · NIAID · WISTAR INSTITUTE · PI Italo Tempera · 2018 to 2026
$3.8M
Epstein-Barr virus LMP1 mediated oncogenicityR01CA228700 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Benjamin Elison Gewurz · 2019 to 2026
$3.3M
Regulation of the Epstein-Barr Virus Lytic SwitchR01AI164709 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Benjamin Elison Gewurz · 2021 to 2026
$3.1M
Characterization of Epstein-Barr Virus Subversion of the Host SMC5/6 Restriction PathwayR21AI170751 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI GEWURZ, BENJAMIN ELISON · 2023 to 2024
$492k
Defining how the DNA- and RNA-binding protein SFPQ represses Epstein-Barr Virus lytic reactivationF32AI172329 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI MURRAY-NERGER, LAURA · 2022 to 2024
$147k
NCI NIH HHS P01 CA269043NCI NIH HHS P30 CA010815NCI NIH HHS R01 CA228700NCI NIH HHS U01 CA275301NIAID NIH HHS F32 AI172329NIAID NIH HHS R01 AI130209NIAID NIH HHS R01 AI164709NIAID NIH HHS R21 AI170751NIAID NIH HHS T32 AI007061NIAID NIH HHS T32 AI007245
6 · The paper itself

Abstract

Epstein-Barr virus (EBV) uses latency programs to colonize the memory B-cell reservoir, and each program is associated with human malignancies. However, knowledge remains incomplete of epigenetic mechanisms that maintain the highly restricted latency I program, present in memory and Burkitt lymphoma cells, in which EBNA1 is the only EBV-encoded protein expressed. Given increasing appreciation that higher order chromatin architecture is an important determinant of viral and host gene expression, we investigated roles of Wings Apart-Like Protein Homolog (WAPL), a host factor that unloads cohesin to control DNA loop size and that was discovered as an EBNA2-associated protein. WAPL knockout (KO) in Burkitt cells de-repressed LMP1 and LMP2A expression, but not other EBV oncogenes, to yield a viral program reminiscent of EBV latency II, which is rarely observed in B-cells. WAPL KO also increased LMP1/2A levels in latency III lymphoblastoid cells. WAPL KO altered EBV genome architecture, triggering formation of DNA loops between the LMP promoter region and the EBV origins of lytic replication (oriLyt). Hi-C analysis further demonstrated that WAPL KO reprogrammed EBV genomic DNA looping. LMP1 and LMP2A de-repression correlated with decreased histone repressive marks at their promoters. We propose that EBV coopts WAPL to negatively regulate latent membrane protein expression to maintain Burkitt latency I.

Indexed as

Epstein-Barr Virus InfectionsGene Expression Regulation, ViralHerpesvirus 4, HumanViral Matrix ProteinsVirus LatencyB-LymphocytesBurkitt LymphomaCell Line, TumorHumansEBV-associated membrane antigen, Epstein-Barr virusViral Matrix Proteins

Identifiers

PMID39241017
PMCPMC11410233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.